Payment overview · 2025
General Payments
$1,169.06
74 reported records · 17 companies
Healthcare provider profile · identity verified
Amr Kahf, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HALEDON, NJ · NPI 1326257668
Verified facts
What the public records show
CMS Open Payments records show Amr Kahf, M.D. received $1,169.06 in general payments during 2025 across 74 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Prolia, Rexulti, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $200.60 | 17.2% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $169.72 | 14.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $156.59 | 13.4% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.86 | 12.2% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $76.00 | 6.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.12 | 6.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.11 | 3.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$39.34 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.37 | 3.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.19 | 3.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.95 | 3.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.80 | 3.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $34.01 | 2.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.12 | 2.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.34 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.30 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.64 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,169.06 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $184.08 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $142.86 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $129.88 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $118.66 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.12 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.41 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $68.92 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $64.85 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $41.11 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $39.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $34.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.12 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.71 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| SPEVIGO Normalized: spevigo |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 201 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 109 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 244 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 104 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 126 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
104 | 28 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
201 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
244 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
43 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
244 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
126 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
271 | 33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
109 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1155 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 110 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 457 | 82 |
| Divalproex Sodium | Divalproex Sodium | 438 | 40 |
| Montelukast Sodium | Montelukast Sodium | 382 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 361 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 61 |
| Gabapentin | Gabapentin | 318 | 59 |
| Metformin Hcl | Metformin Hcl | 285 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 277 | 86 |
| Eliquis | Apixaban | 271 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 54 |
| Risperidone | Risperidone | 255 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 250 | 27 |
| Jardiance | Empagliflozin | 244 | 25 |
| Benztropine Mesylate | Benztropine Mesylate | 235 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 41 |
| Potassium Chloride | Potassium Chloride | 229 | 38 |
| Famotidine | Famotidine | 220 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 48 |
| Mirtazapine | Mirtazapine | 219 | 38 |
| Furosemide | Furosemide | 216 | 35 |
| Lisinopril | Lisinopril | 215 | 49 |
| Omeprazole | Omeprazole | 210 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 202 | 30 |
| Farxiga | Dapagliflozin Propanediol | 201 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 42 |
| Losartan Potassium | Losartan Potassium | 194 | 29 |
| Trazodone Hcl | Trazodone Hcl | 193 | 32 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 191 | 26 |
| Lactulose | Lactulose | 173 | 26 |
| Levetiracetam | Levetiracetam | 163 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 32 |
| Chlorthalidone | Chlorthalidone | 155 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 152 | 34 |
| Ipratropium Bromide | Ipratropium Bromide | 144 | 55 |
| Finasteride | Finasteride | 142 | 23 |
| Ozempic | Semaglutide | 134 | 18 |
| Januvia | Sitagliptin Phosphate | 130 | 23 |
| Mounjaro | Tirzepatide | 126 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 32 |
| Valsartan | Valsartan | 119 | 37 |
| Haloperidol | Haloperidol | 115 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 113 | 16 |
| Gemtesa | Vibegron | 109 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 39 |
| Linzess | Linaclotide | 104 | 28 |
| Prednisone | Prednisone | 100 | 49 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 98 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 96 | 23 |
| Simvastatin | Simvastatin | 96 | 19 |
| Sertraline Hcl | Sertraline Hcl | 89 | 15 |
| Trulicity | Dulaglutide | 89 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 13 |
| Carvedilol | Carvedilol | 81 | 17 |
| Ibuprofen | Ibuprofen | 81 | 33 |
| Memantine Hcl | Memantine Hcl | 81 | 14 |
| Olanzapine | Olanzapine | 80 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 20 |
| Donepezil Hcl | Donepezil Hcl | 77 | 12 |
| Aripiprazole | Aripiprazole | 72 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 70 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 11 |
| Bupropion Xl | Bupropion Hcl | 68 | 13 |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Glimepiride | Glimepiride | 64 | 18 |
| Budesonide | Budesonide | 61 | suppressed |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | suppressed |
| Latanoprost | Latanoprost | 60 | suppressed |
| Baclofen | Baclofen | 59 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 55 | 15 |
| Austedo | Deutetrabenazine | 54 | suppressed |
| Torsemide | Torsemide | 54 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 53 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Topiramate | Topiramate | 48 | suppressed |
| Allopurinol | Allopurinol | 47 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 46 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 12 |
| Creon | Lipase/Protease/Amylase | 45 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 44 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 43 | 43 |
| Hydrocortisone | Hydrocortisone | 43 | 19 |
| Insulin Lispro | Insulin Lispro | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 41 | 22 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 12 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 12 |
| Ondansetron Odt | Ondansetron | 33 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | 12 |
| Procrit | Epoetin Alfa | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | 11 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Victoza 3-Pak | Liraglutide | 23 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | 11 |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 16 | suppressed |
| Abilify Maintena | Aripiprazole | 15 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,169.06 · 74 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, JARDIANCE, LINZESS, MINIMED 780G, MOUNJARO, PROLIA, REXULTI, SPEVIGO, SPRAVATO, TRELEGY ELLIPTA, UZEDY, VRAYLAR, XIFAXAN, YUPELRI, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error